Overexpression of Ang-2 mRNA is associated with non-small cell lung cancer

Serum angiopoietin-2 is a useful clinical marker for detecting non-small cell lung cancer with distant metastasis and is of potential prognostic value.

Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway.

Major lung resection for early stage non-small cell lung cancer leads to a pro-angiogenic status, with increased Ang-2 and decreased Ang-1 productions.

the angiogenic axis Ang-1 and Ang-2/Tie-2 may play an important role in lung cancer development

Serum expression of angiopoietin-2 correlates with survival of non-small cell lung cancer patients.

Angiopoietin-2 might be useful as a prognostic factor for small cell lung cancer (SCLC) and for predicting SCLC response to chemotherapy.

Results demonstrate that Ang-2 expression significantly correlated with poor prognosis for patients with non-small cell lung cancer. [meta-analysis]

the relationship between lung cancer stage and Ang 2 was documented with this study and the expression rate was found to be lower in adenocarcinomas. By this analysis, we can suggest that angiopoietins may be used as an option for targeted treatment in lung cancer.

Results show that MiR-93 targets Ang2 3' UTR and regulates its expression in lung adenocarcinoma.

This systematic review and meta-analysis suggested that serum Ang-2 levels might be a potential predictor for staging, and were associated with prognosis of lung cancer.

Immunoregulation and Clinical Implications of ANGPT2/TIE2(+) M-MDSC Signature in Non-Small Cell lung cancer.